




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor

Re: heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (Moderna) vaccination

Rujittika Mungmunpantipantip^{1,*}, Viroj Wiwanitkit²¹⁾ Private Academic Consultant, Bangkok, Thailand²⁾ Dr DY Patil University, Pune, India

ARTICLE INFO

Article history:

Received 21 May 2022

Accepted 28 May 2022

Available online xxx

Editor: L Leibovici

Keywords:

COVID

Immune

Prevention

Regimen

Vaccine

To the Editor,

We would like to correspond on the publication, "Heterologous gam-covid-vac (sputnik V)/mRNA-1273 (Moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis" [1]. When compared to the homologous SpV/SpV immunisation, Pereson et al. found that the heterologous SpV/Mod combination against SARS-CoV-2 is well tolerated and greatly boosts humoral immune response [1]. We concur that COVID-19 immunisation, in whatever form, can provide protection and has clinical benefits. In this sense, this study can provide some

proof. However, it's important to remember that confounding factors can affect the immunological parameters being assessed. Infection with COVID-19 is common, and it can be re-infected without generating symptoms [2]. Following immunisation, there is a potential of asymptomatic COVID-19, which could make detecting immunological symptoms difficult. The possibility of asymptomatic COVID-19 must be ruled out.

Transparency declaration

The authors declare that they have no conflict of interest. No external funding was received.

Author contributions

RM contributed 50% ideas, writing, analyzing, and final approval for submission. VW contributed 50% ideas, supervising, and final approval for submission.

References

- [1] Pereson MJ, Amaya L, Neukam K, Bare P, Echegoyen N, Noel Badano M, et al. Heterologous gam-covid-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis. *Clin Microbiol Infect* 2022 [Epub ahead of print].
- [2] Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health* 2020;53:70.

DOI of original article: <https://doi.org/10.1016/j.cmi.2022.05.009>.

* Corresponding author. R. Mungmunpantipantip, Private Academic Consultant, Bangkok, Thailand.

E-mail address: rujittika@gmail.com (R. Mungmunpantipantip).

<https://doi.org/10.1016/j.cmi.2022.05.033>

1198-743X/© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.